Palladone-Sr (Hydromorphone Hydrochloride)

Hydromorphone Hydrochloride is an opioid that acts on the central nervous system to relieve pain across several clinical contexts.

• Cancer‑related pain: provides strong analgesia when other opioids are insufficient.
• Post‑operative pain: controls moderate to severe pain after major surgery.
• Chronic non‑cancer pain: used in carefully selected patients requiring long‑term opioid therapy.
• Acute severe pain episodes: offers rapid relief for breakthrough pain attacks.
• Palliative care: improves comfort for patients with life‑limiting illnesses.

• Hydromorphone binds selectively to µ‑opioid receptors in the brain and spinal cord, mimicking endogenous opioids. This binding reduces neuronal excitability, inhibits the release of pain‑transmitting neurotransmitters, and alters pain perception, producing potent analgesic effects without directly affecting inflammatory pathways.

Adverse reactions to hydromorphone may range from mild to life‑threatening and should be monitored throughout therapy.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset common during opioid initiation.
• Constipation: reduced gastrointestinal motility leading to hard stools.
• Drowsiness or sedation: central nervous system depression causing sleepiness.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Dry mouth: reduced salivary flow causing oral discomfort.
• Pruritus: mild itching, often localized.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be fatal.
• Severe hypotension: marked drop in blood pressure.
• Acute adrenal insufficiency: rare hormonal imbalance.
• Allergic reactions: rash, urticaria, or anaphylaxis.
• Dependence and withdrawal: risk of physical dependence with prolonged use.
• Neurotoxicity: rare central nervous system toxicity presenting as confusion or seizures.

When prescribing hydromorphone, clinicians should evaluate patient history, comorbidities, and concomitant medications to minimize risk.

• Assess pain severity and prior opioid response: ensure opioid therapy is appropriate.
• Evaluate respiratory function: avoid use in patients with compromised breathing.
• Review renal and hepatic function: dose adjustments may be needed.
• Monitor for signs of abuse or dependence: implement risk mitigation strategies.
• Counsel on constipation management: use laxatives or stool softeners prophylactically.
• Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Hydromorphone may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: combined CNS depression can cause profound sedation or respiratory failure.
• CNS depressants (e.g., barbiturates, alcohol): additive respiratory depression risk.
• MAO inhibitors: may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): increase hydromorphone plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce analgesic effect.
• Anticholinergics: may worsen constipation.
• Diuretics: can enhance hypotensive effects.
• Serotonergic agents: potential for serotonin syndrome when combined with opioids.